HOPE II Study: Testing a One-Dose HPV Vaccine for Women Living with HIV
The HOPE II Study is looking at whether a single-dose HPV vaccine can help prevent HPV (Human Papillomavirus) infections in women living with HIV, especially those that can lead to cervical cancer. The study focuses on women who have already received the HPV 16/18 vaccine before being diagnosed with HIV. HPV is a leading cause of cervical cancer. By finding the best way to prevent HPV infections in women living with HIV, we can help protect their health and reduce the risk of cervical cancer.
This study is crucial in understanding how to protect women living with HIV from persistent HPV infections, which can cause cancer. It’s an important step towards ensuring healthier futures for these women.
Study Goals:
- To test if a one-dose HPV vaccine can stop infections with high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) in women who have already received the HPV 16/18 vaccine.
- To assess the safety and effectiveness of the vaccine in women living with HIV.
Want to Learn More or Participate? If you want to join the HOPE-II Study or have more questions, contact us via WhatsApp, SMS, or “Please Call Me” at: 076 840 1106
